Tyrosine kinase inhibitors and drug interactions: a review with practical recommendations.
The adverse effects associated to traditional chemotherapy are well known and broadly studied. In the recent years several tyrosine kinase inhibitors have been approved for cancer treatment and numerous are under investigation. These drugs target specific mutated/overexpressed tyrosin kinase receptors and frecuently their pharmacokinetic/pharmacodinamic behavior is not fully elucidated. These new drugs may interact with non-antineoplastic drugs leading to undesirable adverse effects. In this article, we will discuss different types of drug interactions and briefly review the pharmacokinetics and mechanisms of action of tyrosine kinase inhibitors in clinical use, with a particular emphasis on the risk of the occurrence of such interactions based on currently available scientific evidence.
Servicio de Oncología Médica, Hospital Clínico Virgen de la Victoria, Málaga, Spain. bellapajares@yahoo.es
Bella
B
Pajares
Esperanza
E
Torres
José Manuel
JM
Trigo
María Isabel
MI
Sáez
Nuria
N
Ribelles
Begoña
B
Jiménez
Emilio
E
Alba
D000818:Animals; D004347:Drug Interactions; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000201:enzymology*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*
D047428:Protein Kinase Inhibitors; D011505:Protein-Tyrosine Kinases